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Fresenius Medical Care, Bad Homburg, GermanyAchieving an adequate dialysis dose is one of the key goals
for dialysis treatments. Here we assessed whether patients
receiving the current cleared plasma volume (Kt),
individualized for body surface area per recommendations,
had improved survival and reduced hospitalizations at
2 years of follow-up. Additionally, we assessed whether
patients receiving a greater dose gained more beneﬁt. This
prospective, observational, multicenter study included
6129 patients in 65 Fresenius Medical Care Spanish
facilities. Patients were classiﬁed monthly into 1 of 10 risk
groups based on the difference between achieved and
target Kt. Patient groups with a more negative relationship
were signiﬁcantly older with a higher percentage of
diabetes mellitus and catheter access. Treatment dialysis
time, effective blood ﬂow, and percentage of on-line
hemodiaﬁltration were signiﬁcantly higher in groups with a
higher dose. The mortality risk proﬁle showed a
progressive increase when achieved minus target Kt
became more negative but was signiﬁcantly lower in the
group with 1 to 3 L clearance above target Kt and in groups
with greater increases above target Kt. Additionally,
hospitalization risk appeared signiﬁcantly reduced in
groups receiving 9 L or more above the minimum target.
Thus, prescribing an additional 3 L or more above the
minimum Kt dose could potentially reduce mortality risk,
and 9 L or more reduce hospitalization risk. As such, future
prospective studies are required to conﬁrm these dose
effect ﬁndings.
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1332A dequate dialysis dose is one of the most importantgoals in hemodialysis (HD) treatment and should beappropriately prescribed. Achieving a minimum dial-
ysis dose is the responsibility of nephrologists and represents
an area open to improvement. Because age, gender, and co-
morbidity cannot be changed, dialysis parameters should be
adjusted to ensure that the patient receives the optimal
treatment.
Several clinical practice guidelines1–5 have recommended a
minimum Kt/V or urea reduction ratio (URR) as methods for
monitoring dialysis dose. Because the urea kinetic method
requires pre- and post-dialysis urea determinations, moni-
toring is performed monthly, bimonthly, or quarterly, and the
result of this 3% to 7% of total sessions is extrapolated to the
totality of the treatments. Given the relevance of dialysis dose
to survival and that multiple factors can inﬂuence dialytic
efﬁcacy in each session, it seems reasonable to incorporate
biosensors to quantify the dose in each session and in real
time. Most monitors have incorporated ionic dialysance (ID),
which allows calculation of dialysis dose in all sessions,
without involving any additional workload, analytical de-
terminations, or cost.6 Consequently, many dialysis units have
already abandoned urea determinations.
In 1999, Lowrie et al.7 proposed Kt as a method of moni-
toring dialysis dose and mortality. These authors observed a J-
shaped survival curve when they distributed the patients into
quintiles from the smallest to the highest URR, while the curve
descended with Kt for the same patients.8 In 2005, the mini-
mumKt dose was individualized according to body surface area
(BSA)9 and validated in a further study.10 Since 2006, the
Guidelines of the Spanish Society of Nephrology5 have pro-
posed that dialysis centers with dialysis machines that have
ionic dialysance use Kt to monitor dialysis dose.
The Optimizing Results in Dialysis research initiative
began in 2010 with the aim of improving HD patient out-
comes by elucidating patient characteristics and practice of
care in Spain.11 In a previous retrospective study published by
this group,12 monitoring the dialysis dose with Kt instead Kt/
V was evaluated. The authors concluded that the advantage of
this method is that it identiﬁes 25.8% of patients who did not
reach the minimum Kt while achieving Kt/V. This differenceKidney International (2016) 90, 1332–1341
F Maduell et al.: Adequate Kt dose c l i n i ca l i nves t iga t ionwas particularly evident in women, patients with low body
weight, and those with a venous central catheter (VCC).
To deﬁne and validate the minimum Kt recommendations
in the current Spanish dialysis population, therefore, the aim
of the Optimizing Results in Dialysis research initiative was to
design this prospective, observational, multicenter study. The
goal was to assess whether patients receiving the current
recommendations for an adequate dialysis dose by Kt indi-
vidualized for BSA had improved survival and reduced hos-
pitalizations at 2 years compared to those who did not. In
addition, we assessed whether patients receiving a greater
dose experienced greater beneﬁt.
RESULTS
Baseline patient characteristics
During the recruitment period, 8095 patients were assessed
for eligibility in 65 Fresenius Medical Care (FMC) Spanish
facilities. Following the inclusion criteria, 6129 patients
were subsequently included in this prospective study
(Supplementary Table S1). The mean age was 68.9  14 years,
62.3% were male, 65.5% had cardiovascular risk factors,
36.4% had diabetes mellitus, and the mean Charlson index
was 5.5  1.9. Vascular access through an autologous arte-
riovenous ﬁstula (AVF) was present in 67.9% of patients,
through a prosthetic arteriovenous ﬁstula in 3.8%, and
through VCCs in 28.3%.
Patients were categorized monthly into 1 of 10 risk groups
based on the difference between achieved Kt and target Kt
(achieved–targetKt). The inﬂuences of patient characteristics per
each dialysis dose group are summarized in Table 1. The
patient groups that had a more negative relationship with the
achieved–targetKt were signiﬁcantly older and had a higher per-
centage of diabetes mellitus, higher comorbidity index, and
higher percentage of catheters as vascular access. By contrast,
the groups were balanced for gender and for the percentage of
patients with cardiovascular risk.
HD treatment
The mean effective dialysis duration (Td) was 240.3 14 min,
blood ﬂow rate (QB) was 413  64 ml/min, dialysate ﬂow rate
was 51110 ml/min, and dry body weight was 69.7  15 kg.Table 1 | Patient characteristics and baseline parameters in the
achieved–targetKt categories
(L) Number Age (yr) Gender (% female) CV risk
< –8 203 72.2 (11.8) 36.95 66.5
–8 to –4 274 73.0 (11.6) 41.24 64.9
–4 to –1 435 71.8 (12.8) 40.46 64.3
–1 to þ1 437 71.6 (13.4) 40.73 60.8
1 to þ3 579 70.4 (13.4) 38.69 65.8
3 to þ6 1000 69.8 (13.5) 35.50 64.6
6 to þ9 1093 68.6 (14.1) 36.41 67.0
9 to þ12 918 68.0 (14.8) 38.89 64.6
12 to þ15 641 66.1 (15.7) 34.48 69.8
> þ15 549 63.1 (16.9) 38.62 64.8
P value <0.001 0.25 0.2
Data are presented as mean (SD), percentages (%), or median and interquartile range (
CI, Charlson Index (age adjusted); CV, cardiovascular; DM, diabetes mellitus; VA, venous
Kidney International (2016) 90, 1332–1341Post-dilution online hemodiaﬁltration (HDF) treatments were
performed for a total of 45.3% of the sessions, and the mean
substitution volume was 24.2  3.6 L. High-ﬂux nonreusable
dialyzers usedwere FX-50 (0.02%), FXCorDiax 60 (50.9%), FX
CorDiax 600 (38.9%), FX CorDiax 80 or 800 (8.8%), FX
CorDiax 1000 (0.2%), (FreseniusMedical Care, BadHomburg,
Germany), and Sureﬂux (Nipro, Osaka, Japan) 19UX or 21L
(1.1%).
The mean target Kt was 48.6  3.8 L, and the
mean achieved Kt was 55.1  9.3 L. Moreover, the median
achieved–targetKt was 6.4 (1.7–10.8) L, ranging from –20.1
to þ30.5 L. In addition, the minimum target Kt dose was
achieved in 80.5% of patients. Nevertheless, signiﬁcant dif-
ferences were found for the percentage of women who ach-
ieved the target Kt dose compared with men (79.0% vs.
81.5%; P < 0.001). Signiﬁcant differences also were found
between the percentage of sessions with the target Kt achieved
and performed by VCC or AVF (59.2% vs. 88.9%; P < 0.001).
Length of effective treatment dialysis time and QB were
signiﬁcantly longer in groups with higher achieved–targetKt (P <
0.001, both). In contrast, the lower adjusted Kt groups
showed signiﬁcantly lower percentages with the online HDF
treatment option (P < 0.001) (Figure 1).Albumin, C-reactive protein, and hemoglobin proﬁles
The patients included in the project had average albumin
levels from 3.6 to 3.9 g/dl. Despite the short range, signiﬁcant
differences were found between groups (Figure 2a). The
corresponding post hoc Scheffé test revealed signiﬁcant dif-
ferences comparing the ﬁrst achieved–targetKt group (lower than
–8 L) to the 5 highest groups analyzed (from þ3 L and up).
Patients had median C-reactive protein levels of 5.0 (1.8–
12.1) mg/l. ANOVA for the logarithmic-transformed variable
indicated signiﬁcant differences for the groups (P < 0.001),
and the Scheffé test showed that the patients included in the 2
ﬁrst achieved–targetKt groups (the <–8 L group and the –4 to –1
L group) had higher levels of C-reactive protein compared to
the last 4 groups (þ6 to þ9 L group and up) (Figure 2b). This
result is consistent with the higher percentage of catheters
used in these groups (Table 1).10 groups based on Kt individualized or body surface area
(%) DM (%) CI Weight (kg) VA (%) Kt/V (median) Kt/V on target
0 46.80 6.1 (1.9) 76.4 (19.6) 80.79 1.26 (1.11–1.43) 27.8%
6 44.16 6.0 (1.7) 73.5 (16.9) 77.37 1.45 (1.32–1.62) 62.0%
7 42.30 5.9 (1.8) 72.8 (15.0) 71.03 1.57 (1.46–1.71) 84.4%
7 45.54 5.9 (1.8) 71.9 (15.8) 62.70 1.65 (1.51–1.80) 90.3%
0 41.28 5.7 (1.9) 71.6 (15.4) 54.92 1.71 (1.53–1.89) 91.8%
0 41.00 5.6 (1.9) 70.9 (14.2) 40.80 1.78 (1.61–1.97) 97.0%
6 36.14 5.4 (1.9) 69.6 (14.1) 30.10 1.85 (1.68–2.07) 98.2%
0 32.24 5.3 (1.9) 67.7 (14.2) 22.66 1.96 (1.76–2.22) 98.9%
9 28.08 5.2 (2.0) 66.7 (13.9) 17.16 2.06 (1.84–2.31) 99.7%
5 20.58 4.7 (1.9) 63.2 (14.4) 11.29 2.22 (1.93–2.51) 99.8%
1 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
25th–75th percentile).
central catheter.
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Figure 1 | Inﬂuence of hemodialysis treatment parameters for
different categories of achieved–targetKt. The bars represent the
percentage of patients on the HDF treatment option, left axis, for
each adjusted Kt category. The squares (-) represent the mean
effective blood ﬂow and the triangles (:) the mean effective
treatment time for the patients classiﬁed on each adjusted Kt
category, right axis.
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Figure 2 | The analytical proﬁles for different categories of
achieved–targetKt. (a) Albumin. (b) C-reactive protein. (c) Hemoglobin.
*P < 0.05 by post hoc Scheffé test.
c l i n i ca l i nves t iga t i on F Maduell et al.: Adequate Kt doseFinally, the average hemoglobin values for each group
ranged from 11.1 to 11.7 g/dl. Again, despite the narrowness
of this range, ANOVA revealed signiﬁcant differences among
groups (P < 0.001). Of interest, the post hoc test showed that
groups with better outcomes for achieved–targetKt had signiﬁ-
cantly lower levels of hemoglobin compared to the 3 highest
groups (Figure 2c).
Factors inﬂuencing achievement of target Kt
To identify different predictors that could affect the
nonachievement of the target Kt, unadjusted and adjusted
generalized linear mixed models were constructed. In every
case, these models were built considering repeated measures
nested within patients. Moreover, the different Spanish FMC
facilities involved in the study were introduced into the
different models as a random effect component. The corre-
sponding ORs (odds ratios) and 95% conﬁdence intervals
(CIs) are shown in Table 2. After the analysis of a total of
1,076,252 HD sessions, we found that all covariates recorded
could affect the outcome. Among nonmodiﬁable factors, the
presence of diabetes mellitus was the covariate associated with
a higher risk of not achieving the target Kt, whereas VCC was
identiﬁed among the modiﬁable factors. On the other hand,
patients treated by HDF had a signiﬁcantly higher probability
of making the target Kt.
Mortality
Patients were monitored for 2 years or until premature
termination or death. During the observation period, 7901334 Kidney International (2016) 90, 1332–1341
Table 2 | Generalized Linear Mixed Models to identify ﬁxed effects predictors with a potential negative impact on achieving the
Kt individualized for body surface area target
Univariate Multivariate
P OR
95% CI
P OR
95% CI
Lower Upper Lower Upper
Non–modiﬁable factors Vintage (yr) Ref: <2.00 – – – – – – – –
2.00 – 2.99 0.979 1.000 0.985 1.014 0.002 1.027 1.012 1.043
3.00 – 4.99 0.118 1.010 0.997 1.024 <0.001 1.053 1.039 1.068
5.00 – 8.00 <0.001 1.026 1.013 1.039 <0.001 1.047 1.033 1.061
>8.00 <0.001 0.960 0.947 0.972 0.034 1.015 1.001 1.030
Gender Ref: female <0.001 1.055 1.047 1.064 <0.001 1.026 1.012 1.043
CV risk Ref: No 0.480 1.003 0.995 1.011 – – – –
DM Ref: No <0.001 1.140 1.131 1.150 <0.001 1.042 1.033 1.052
Age (yr) Ref: < 51.00 – – – – – – – –
51.00 – 60.00 <0.001 1.086 1.068 1.104 0.086 0.985 0.967 1.002
61.00 – 70.00 <0.001 1.113 1.096 1.130 0.011 0.979 0.964 0.995
71.00 – 80.00 <0.001 1.183 1.166 1.200 0.291 0.992 0.977 1.007
>80.00 <0.001 1.232 1.215 1.250 0.660 0.986 0.970 1.002
Modiﬁable factors HDF Ref: HD <0.001 0.670 0.665 0.675 <0.001 0.787 0.780 0.794
VCC Ref: AVF <0.001 1.912 1.896 1.929 <0.001 1.332 1.318 1.346
Weight (kg) Ref: < 58.00 – – – – – – – –
58.00 – 64.00 0.268 0.993 0.980 1.006 <0.001 1.109 1.094 1.124
65.00 – 72.00 <0.001 1.042 1.029 1.055 <0.001 1.195 1.179 1.211
73.00 – 81.00 <0.001 1.078 1.064 1.092 <0.001 1.306 1.288 1.325
>81.00 <0.001 1.190 1.175 1.250 <0.001 1.524 1.503 1.546
QB (ml/min) <0.001 0.994 0.994 0.995 <0.001 0.995 0.994 0.995
Td (min) <0.001 0.983 0.982 0.984 <0.001 0.984 0.983 0.984
Albumin (g/dl) < 3.50 <0.001 1.163 1.146 1.174 0.011 1.018 1.004 1.031
3.50 – 4.00 <0.001 1.058 1.049 1.068 0.005 1.014 1.004 1.024
Ref: >4.00 – – – – – – – –
Hb (g/dl) < 10.00 <0.001 0.939 0.926 0.952 <0.001 0.918 0.905 0.932
10.00 – 11.00 <0.001 0.965 0.955 0.952 <0.001 0.962 0.952 0.973
Ref: 11.00 – 12.00 – – – – – – – –
12.00 – 13.00 <0.001 1.085 1.073 1.098 <0.001 1.056 1.043 1.069
>13.00 <0.001 1.295 1.278 1.313 <0.001 1.221 1.203 1.238
CRP (mg/l) Ref: < 1.20 – – – – – – – –
1.20 – 3.40 0.689 1.003 0.990 1.016 0.770 1.002 0.989 1.015
3.40 – 7.00 <0.001 1.053 1.040 1.067 0.002 1.021 1.008 1.035
7.00 – 15.00 <0.001 1.079 1.065 1.093 <0.001 1.036 1.023 1.050
>15.00 <0.001 1.103 1.089 1.118 <0.001 1.053 1.039 1.068
Generalized Linear Mixed Models considering repeated measures nested within patients; the different Spanish Fresenius Medical Care facilities were introduced in the model
as a random effect component; link function: logarithmic.
CRP, C–reactive protein; CV, cardiovascular; DM, diabetes mellitus; Hb, hemoglobin; HDF, hemodiaﬁltration; QB, blood ﬂow; Td, effective treatment time; VCC, venous central
catheter.
F Maduell et al.: Adequate Kt dose c l i n i ca l i nves t iga t ionpatients prematurely exited the study because of kidney
transplantation (n ¼ 685), change in dialysis unit (n ¼ 62), or
other reasons (n ¼ 43). All of these patients were censored at
the time of premature termination.
There were 1004 deaths (16.4%) during the follow-up. The
main causes of death were cardiovascular diseases (45.6%),
infectious diseases (17.9%), sudden death (10.4%), gastroin-
testinal diseases (6.2%), tumor (5.2%), and other (14.7%).
The independent predictors for all-cause mortality were
identiﬁed exploring the nonlinear effects of the continuous
variables. The corresponding univariate time-dependent Cox
model is shown in Table 3. Moreover, the possible center
effect on the outcome was identiﬁed as a nonsigniﬁcant co-
variate in a univariate analysis (Supplementary Table S2). The
independent predictors for all-cause mortality were age,
gender, cardiovascular risk, diabetes mellitus, VCC, weight,
hemoglobin, albumin, C-reactive protein, and achieved–targetKt.Kidney International (2016) 90, 1332–1341To assess whether patients receiving an adequate dialysis
dose could have a reduced mortality risk, unadjusted and
adjusted time-dependent Cox analyses were performed. All
covariates that were previously identiﬁed as independent
predictors for all-cause mortality were introduced into the
Cox adjusted model. The reference group selected was the one
that incorporated the null value (achieved–targetKt –1 to þ1 L/
treatment). Results with hazard ratios (HRs) for each group
are shown in Figure 3.
The mortality risk proﬁle showed a signiﬁcant trend (P <
0.001) toward a progressive increase in mortality risk with
increasingly negative achieved–targetKt. The HR for the lower
achieved–targetKt group was associated with signiﬁcantly higher
mortality risk (univariate HR, 1.69; 95% conﬁdence interval
[CI], 1.25 to 2.28; P < 0.001; multivariate HR, 1.95; 95% CI,
1.41 to 2.71; P < 0.001). Of interest, the HR fell as the achieved–
targetKt parameter moved into the positive range and became1335
Table 3 | Univariate and multivariate time dependent Cox regression analysis for all–cause mortality with variables grouped as
nonmodiﬁable or modiﬁable factors
Time dependent Cox model
Univariate Multivariate
P HR
95% CI
P HR
95% CI
Lower Upper Lower Upper
Non–modiﬁable factors Gender Ref: female 0.01 1.407 1.083 1.828 0.003 1.240 1.078 1.425
CV Risk Ref: No 0.04 1.120 1.102 1.278 0.888 1.010 .879 1.161
DM Ref: No <0.001 1.322 1.166 1.498 0.004 1.214 1.063 1.386
Age (yr) Ref: < 51.0 – – – – – – – –
51.0 – 60.0 0.025 1.694 1.068 2.686 0.345 1.257 0.782 2.019
61.0 – 70.0 <0.001 3.250 2.175 4.858 <0.001 2.267 1.507 3.412
71.0 – 80.0 <0.001 4.531 3.079 6.668 <0.001 2.859 1.929 4.236
>81.0 <0.001 6.364 4.344 9.323 <0.001 3.520 2.379 5.208
Modiﬁable factors achieved–targetKt (L) <0.001 0.950 0.942 0.958 <0.001 0.945 0.933 0.957
HDF Ref: HD 0.01 0.845 0.742 0.961 0.110 0.883 0.758 1.029
VCC Ref: AVF <0.001 1.499 1.324 1.697 0.036 1.173 1.011 1.362
Weight (kg) Ref: < 58.0 – – – – – – – –
58.0 – 64.0 <0.001 0.721 0.605 0.860 0.003 0.757 0.630 0.910
65.0 – 72.0 <0.001 0.640 0.538 0.762 <0.001 0.604 0.500 0.729
73.0 – 81.0 <0.001 0.507 0.416 0.618 <0.001 0.484 0.390 0.602
>81.0 <0.001 0.416 0.339 0.511 <0.001 0.415 0.328 0.527
Td (min) <0.001 0.983 0.979 0.987 0.305 1.003 0.998 1.008
Albumin (g/dl) < 3.5 <0.001 4.905 4.091 5.881 <0.001 2.383 1.939 2.930
3.5 – 4.0 <0.001 1.775 1.501 2.098 0.005 1.293 1.080 1.547
Ref: >4.0 – – – – – – – –
Hb (g/dl) < 10.0 <0.001 6.127 4.970 7.553 <0.001 5.188 4.151 6.485
10.0 – 11.0 <0.001 1.672 1.437 1.945 <0.001 1.642 1.406 1.918
Ref: 11.0 – 12.0 – – – – – – – –
12.0 – 13.0 <0.001 1.424 1.172 1.732 <0.001 1.436 1.166 1.769
>13.0 0.032 1.329 1.024 1.726 0.084 1.277 0.967 1.686
CRP (mg/l) Ref: < 1.2 – – – – – – – –
1.2 – 3.4 0.381 1.168 0.825 1.653 0.728 1.064 0.750 1.510
3.4 – 7.0 0.034 1.426 1.027 1.979 0.378 1.161 0.833 1.619
7.0 – 15.0 0.002 1.622 1.186 2.219 0.350 1.164 0.846 1.603
>15.0 <0.001 3.596 2.672 4.841 <0.001 2.032 1.493 2.766
The plausible center effect was identiﬁed as a nonsigniﬁcant variable in a univariate analysis.
CRP, C-reactive protein; CV, cardiovascular risk; DM, diabetes mellitus; Hb, hemoglobin; HDF, hemodiaﬁltration; Td, effective treatment time; VCC, venous central catheter.
c l i n i ca l i nves t iga t i on F Maduell et al.: Adequate Kt dosesigniﬁcantly lower at the þ1 to þ3 L group and up for both
univariate and adjusted models. From þ9 L and up, the
mortality risk proﬁle remained ﬂattened and signiﬁcantly
lower than the reference group (Figure 3).
Further Cox models were used for the analysis of different
causes of death that were identiﬁed as represented in >10% of
cases. We found signiﬁcant differences for these outcomes
(Table 4). The risk appeared to be lower as the achieved–targetKt
parameter moved into the positive range for cardiovascular,
sudden death, and infection-related mortality, from þ6
to þ9 L and up.
Sensitivity analysis for the main outcome: Mortality and
target Kt
Reviewing the demographic features of the study groups
(Table 1), it would be expected that the more elderly and frail
groups and those with catheter access would fail to achieve
target Kt (Table 2) and therefore have greater mortality rates.
Thus, although the previous adjusted Cox models included all
of the independent mortality predictors collected for this
study, we cannot exclude a reverse-causality phenomenon. To
address this problem, we decided to use a propensity score
matching approach. We combined the 10 study categories
into 2 population groups according to baseline HD dose:1336equal to or less than the reference dose group (achieved–targetKt
–1 to þ1 L) and greater than the group with reduced mor-
tality according to our predictive models (þ1 to þ3 L). We
tried to balance these 2 resulting populations for every co-
variate described as predictors with an impact on achieving
the target Kt (Table 2). The resulting balanced population was
properly assessed (Supplementary Table S3), and the adjusted
cohort was used to estimate the corresponding mortality risk.
The Cox model indicated that having an HD dose deﬁned as
achieved–targetKt above þ1 L was associated with a 25%
reduction in risk for all-cause mortality compared to the
lower HD group (< þ1 L) (HR, 0.753; 95% CI, 0.578–0.979;
P ¼ 0.034).
Hospital admission
There were 6939 hospital admissions for 3042 of the total
included patients (49.6%) during the follow-up. The main
causes of hospital admissions were vascular access (15.3%),
cardiovascular diseases (16.5%), infectious diseases (19.2%),
digestive diseases (10.6%), respiratory diseases (6.0%), and
other (32.4%).
Again, a negative trend (P < 0.001) in hospitalization risk
with the progressive increases in dialysis dose was identiﬁed
(Figure 4). In both models, the HR increased progressively asKidney International (2016) 90, 1332–1341
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means no signiﬁcant differences. Bars ¼ 95% conﬁdence intervals.
F Maduell et al.: Adequate Kt dose c l i n i ca l i nves t iga t ionthe achieved–targetKt groups became more negative. On the
other hand, as occurred in the mortality risk models, the
hospitalization risk appeared to decrease until the last achieved–
targetKt group, becoming signiﬁcant with the þ6 to þ9 L
group in the univariate model and with the þ9 to þ12 L
group in the multivariate model.DISCUSSION
In this study, the current recommendations for monitoring
dialysis dose with Kt individualized for BSA were validated in
the current Spanish dialysis population and found to be
suitable. A dose higher or lower than the recommended
minimum is predictably associated with lower or higher death
and hospitalization risk. To our knowledge, this is the ﬁrst
prospective trial showing that prescribing more than 1 to 3 L
of the current Kt individualized for BSA recommendations
reduces mortality risk and more than 9 L reduces hospitali-
zation risk. Thus, both adjusted and unadjusted risk proﬁle
results indicated that an adequate dialysis dose as measured
by Kt individualized for BSA improved the morbidity–mor-
tality rate in HD patients.
Traditionally, dialysis dose recommendations are based on
analytical pre- and post-dialysis urea determinations. US,
European, Canadian, United Kingdom, and Spanish guide-
lines1–5 recommend a minimum Kt/V of 1.2 and/or a URR of
65% (or Kt/V of 1.3 and a URR of 70% to ensure that these
minimum requirements are reached). If urea measurements
are carried out only monthly, bimonthly, or quarterly to
calculate the dialysis dose, the results from this 3% to 7% of
the total sessions will be extrapolated to everything that oc-
curs in all sessions. Because multiple factors can inﬂuence
dialytic efﬁcacy in each HD session, control systems haveKidney International (2016) 90, 1332–1341been developed to quantify the dose received by the patient in
each session and in real time. Most monitors have incorpo-
rated ID, which allows the dialysis dose to be calculated in all
sessions, without involving additional workload, analytical
determinations, or cost.6 Consequently, many dialysis units
have already abandoned urea determinations. In contrast, the
lack of the predialysis and postdialysis serum urea measure-
ments entails unknown information about the urea genera-
tion rate and net protein catabolic rate as a protein intake
guide.
Various authors who have used ID in HD and expressed ID
as Kt/V have concluded that Kt/V readings through ID differ
from analytical readings, although the correlation between
both procedures is good,13,14 which demonstrates variability
between the methods used. To obtain Kt/V, the V must be
introduced, but it is an inaccurate value that can be obtained
by anthropometric equations such as Watson’s, by calculating
the measured Kt divided by the analytical Kt/V, or by
bioelectrical impedance.15 Kt/V determined by ID is normally
underestimated compared with pre- to post-dialysis anal-
ysis.13,14,16,17 For these reasons, Kt/V with ID has not been
validated yet.
With the incorporation of ID, Kt instead of Kt/V was
proposed as a method to monitor dialysis dose7 because it
enables avoidance of the J-shaped survival curve, which oc-
curs when patients are distributed according to the URR or
Kt/V.8 In a previous study, minimum Kt dose was individu-
alized in terms of BSA9 and validated in 59,644 North
American FMC patients in a cross-sectional study (March
2004) as a predictor measure during a 1-year period.10 In the
Spanish population, monitoring the dialysis dose with Kt
instead of Kt/V identiﬁes from 25% to 40% of patients who
did not reach the minimum Kt while achieving Kt/V,12,18,19
particularly in women, patients with VCC, and those with a
low body weight.12
Some authors since have proposed rescaling standard Kt/V
to BSA20,21 or using alternative methods instead of V for
scaling the dialysis dose.22 However, incorporation of these
alternatives into clinical practice has not been widely accepted
because of the difﬁculty in making appropriate calculations.
In our opinion, the use of Kt is simple because it is provided
directly by the monitor and its use has been directly pro-
portional to the incorporation of biosensors with ID.
The real possibility of continuous dialysis dose moni-
toring has been reﬂected in the growing interest in quality
policies regarding adequate dialysis treatment. In a 2006
study in a US dialysis population,10 the mean delivered Kt
was 51 L and mean achieved–targetKt was þ0.3 L. In a 2013
study in a Spanish dialysis population,12 the mean delivered
Kt was 52.6 L and the mean achieved–targetKt was þ3.3 L. In
the current study, also in a Spanish dialysis population, the
mean delivered Kt was 55.1 L and the mean achieved–targetKt
was þ6.5 L. These results reﬂect HD adequacy improvement
in the last 10 years, with the minimum Kt achieved in 53%,
67%, and 81%, respectively. The present study supports
achieved–targetKt as an independent mortality risk factor and1337
Table 4 | Primary outcome: mortality
Death cause and number of events achieved–targetKt
Univariate Multivariate
P value HR
95.0% CI
P value HR
95.0% CI
Lower Upper Lower Upper
Death from any cause
1004
< –8 0.001 1.688 1.251 2.277 <0.001 1.954 1.405 2.717
–8 to –4 0.283 1.181 0.872 1.598 0.658 1.076 0.779 1.486
–4 to –1 0.452 0.898 0.678 1.189 0.619 0.930 0.697 1.240
–1 to þ1 Ref. – – – Ref. – – –
þ1 to þ3 0.008 0.686 0.519 0.906 0.008 0.678 0.508 0.904
þ3 to þ6 0.001 0.649 0.507 0.830 0.022 0.745 0.579 0.959
þ6 to þ9 <0.001 0.563 0.439 0.721 <0.001 0.583 0.450 0.755
þ9 to þ12 <0.001 0.490 0.377 0.637 <0.001 0.485 0.368 0.640
þ12 to þ15 <0.001 0.394 0.291 0.533 <0.001 0.391 0.285 0.536
> þ15 <0.001 0.420 0.307 0.574 <0.001 0.364 0.259 0.511
Cardiovascular cause
458 (45.62%)
< –8 0.419 1.225 0.749 2.003 0.219 1.395 0.821 2.372
–8 to –4 0.439 1.194 0.762 1.871 0.490 1.185 0.732 1.917
–4 to –1 0.570 0.886 0.583 1.346 0.952 0.987 0.641 1.519
–1 to þ1 Ref. – – – Ref. – – –
þ1 to þ3 0.067 0.677 0.447 1.027 0.119 0.711 0.464 1.092
þ3 to þ6 0.056 0.704 0.491 1.009 0.172 0.771 0.531 1.119
þ6 to þ9 0.001 0.537 0.370 0.779 0.002 0.533 0.360 0.789
þ9 to þ12 0.001 0.517 0.352 0.761 <0.001 0.457 0.299 0.697
þ12 to þ15 <0.001 0.428 0.276 0.663 <0.001 0.359 0.220 0.584
> þ15 0.001 0.484 0.310 0.755 <0.001 0.346 0.205 0.584
Infection
180 (17.93%)
< –8 0.030 2.046 1.072 3.906 0.031 2.077 1.070 4.032
–8 to –4 0.919 0.962 0.461 2.009 0.324 0.661 0.290 1.504
–4 to –1 0.233 1.418 0.799 2.517 0.417 1.275 0.709 2.294
–1 to þ1 Ref. – – – Ref. – – –
þ1 to þ3 0.560 0.835 0.456 1.530 0.579 0.840 0.454 1.555
þ3 to þ6 0.021 0.497 0.274 0.899 0.095 0.601 0.331 1.093
þ6 to þ9 0.016 0.490 0.274 0.878 0.025 0.509 0.282 0.920
þ9 to þ12 0.003 0.386 0.204 0.731 0.005 0.396 0.208 0.753
þ12 to þ15 <0.001 0.203 0.086 0.480 0.001 0.216 0.091 0.513
> þ15 0.001 0.243 0.103 0.575 0.001 0.210 0.083 0.530
Sudden death
104 (10.36%)
< –8 0.231 1.746 0.702 4.340 0.354 1.607 0.589 4.385
–8 to –4 0.074 2.078 0.931 4.638 0.151 1.849 0.798 4.282
–4 to –1 0.244 0.554 0.205 1.498 0.189 0.491 0.170 1.419
–1 to þ1 Ref. – – – Ref. – – –
þ1 to þ3 0.389 0.686 0.291 1.616 0.218 0.563 0.226 1.405
þ3 to þ6 0.365 0.709 0.338 1.491 0.390 0.717 0.336 1.532
þ6 to þ9 0.032 0.409 0.181 0.928 0.020 0.374 0.163 0.857
þ9 to þ12 0.124 0.538 0.244 1.186 0.034 0.410 0.180 0.935
þ12 to þ15 0.021 0.310 0.115 0.839 0.003 0.207 0.073 0.593
> þ15 0.030 0.309 0.107 0.890 0.002 0.168 0.054 0.528
The variables included in the multivariate analysis were gender, cardiovascular risk, diabetes mellitus, age, treatment option, vascular access, weight, effective treatment time,
albumin, hemoglobin, C-reactive protein and Spanish Fresenius Medical Care facilities. Variables not deemed signiﬁcant were excluded from ﬁnal analysis.
c l i n i ca l i nves t iga t i on F Maduell et al.: Adequate Kt doseprovides evidence that if minimum target Kt is increased 1 to
3 L or more, the risk of all-cause and cardiovascular mor-
tality could be reduced. Thus, our proposal to improve
survival should be an increment in the minimum target Kt
of approximately 5% to maintain achieved–targetKt from 1 to
3 L or higher (Figure 5).
Several groups have shown that the general Kt/V recom-
mendations could lead to under-dialysis in women.23–25 In a
previous study, we found that achievement of minimum Kt
recommendations was lower in women than men (63% vs.
69%, respectively) while in the present study, we observed an
improvement in both sexes (79% vs. 81.5%), although a
signiﬁcant difference persisted.
The risk of under-dialysis increased in patients with VCC.
In European countries, the use of tunneled VCC has gradually
increased as a permanent form of vascular access.26 Maduell1338et al.27 suggested that the Td should be lengthened by 30 min
if a catheter is used in the normal position and by 60 min if in
an inverted position. In the present study, although the per-
centage of patients with VCC was 1.6% higher than in a study
conducted 3 years ago and represented the main factor for not
achieving the target Kt, the percentage of patients who
reached the target Kt was higher (58%) versus 3 years ago
(38%). The causes of this improvement likely were the use of
better catheters providing higher QB (337  87 vs. 363  65
ml/min) and an increment of Td (234.8  17 vs. 240.4  13
min). Therefore, this study conﬁrms that Td should be
increased in patients dialyzed with VCC, speciﬁcally by 20
min to achieve the target Kt.
Online HDF always increases dialysis dose and reduces the
infra-dialysis risk. The high percentage of patients receiving
high-volume online HDF in this work conﬁrms that thisKidney International (2016) 90, 1332–1341
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Figure 4 | Hospitalization risk proﬁles for achieved–targetKt groups.
Unadjusted (C) and adjusted (-) analyses are shown. The HRs are
comparedwith a common reference category (Ref.) for each analysis. The
probability thateachratio isnotdifferent fromits referencevalue is shown
by a symbol near the ratio: # P< 0.001; P< 0.01;þ P< 0.05; no symbol
means no signiﬁcant differences. Bars ¼ 95% conﬁdence intervals.
F Maduell et al.: Adequate Kt dose c l i n i ca l i nves t iga t ionmodality of treatment is associated with survival in the uni-
variate analysis, conﬁrming results of the ESHOL study,28
pooling 4 main randomized clinical trials29 and meta-ana-
lyses.30 Our results suggest that the mortality beneﬁt provided
by online HDF is partly related to a higher dialysis dose;
however, the present study was not designed to evaluate the
effect of online HDF on mortality, and the sample size and
follow-up time are underpowered for such an analysis.0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
Unadjusted Model
Adjusted Model
+ x #
+ # x
achieved–targetKt categories (L)
M
or
ta
lit
y 
H
R
#
#
x
#
x + x
Ref.
Figure 5 | Proposal to improve survival by increasing the target
Kt toD1 toD3 L achieved–targetKt. Unadjusted (C) and adjusted (-)
analyses are shown. The HRs are compared with a common reference
category (Ref.) for each analysis. The probability that each ratio is not
different from its reference value is shown by a symbol near the ratio:
# P < 0.001;  P < 0.01; þ P < 0.05; no symbol means no signiﬁcant
differences. Bars ¼ 95% conﬁdence intervals.
Kidney International (2016) 90, 1332–1341Cardiovascular, infectious, and sudden deaths represented
74% of mortality causes in our study and were also inﬂuenced
by dialysis dose received. An increment achieved–targetKt
above 6 to 9 L could reduce mortality risk 47%, 60%, and
48%, respectively.
The observational design of this study does not allow for
establishing a causal relationship between dialysis dose and
mortality. It is important to keep in mind that the HEMO
study31 is the sole randomized clinical trial designed to assess
the effect of dialysis dose, and since that trial, clinical guide-
lines have given Kt/V $ 1.2 as the minimum recommended
dose. Moreover, it is important to consider that the dose-
targeting bias was revealed under the controlled conditions
of the HEMO study, which emphasizes that caution is
necessary when interpreting nonrandomized relationships
between dialysis dose and outcome.32 To address this issue, we
have applied propensity score matching in our sample of pa-
tients showing that patients receiving a higher dialysis dose
have a reduced mortality risk independent of the other
comorbidities. The progressive incorporation of ionic dialy-
sance monitors in dialysis units has changed substantially, and
to reﬂect this changing reality for monitoring dose, new
randomized trials would be required. Our results suggest that
mortality can be further reduced with higher Kt adjusted for
BSA dose. In order to test this hypothesis we understand that a
prospective, randomized study will be needed, allocating pa-
tients with achieved–targetKt from 1 to 3 L (minimum target
dose) to maintain this dose or to increase it to higher than 9 L.
This study has some weaknesses but also major strengths.
A limitation is that the residual renal function was not
monitored, and it has been associated with better survival in
HD patients33 and may confound the dialysis dose–mortality
association. The strengths of this study include the large
sample size and prospective long follow-up, as well as
reﬂecting current HD treatment, including the high convec-
tive mode.
In conclusion, current recommendations for monitoring
the dialysis dose with Kt individualized for BSA have been
validated in this prospective study in the current Spanish
dialysis population, and the dose is predictably associated
with death and hospitalization risk. Prescribing an additional
3 L or more of the current Kt individualized for BSA could
reduce the risk of mortality, and an additional 9 L or more
could reduce the risk of hospitalization.
METHODS
Study design
The clinical trial was designed as a noninterventional, prospective,
observational, multicenter study in end-stage renal disease patients
undergoing HD performed in all of the Spanish FMC facilities. All
included patients signed the appropriate consent form approved by
the Hospital Ethics Committee and also for their introduction to the
EuCliD database, the Fresenius Medical Care clinical data system.34
The registered protocol number for this trial is NCT 01932853.
The primary objective was to assess whether patients receiving
the current recommendations of an adequate dialysis dose by Kt
individualized for BSA have improved survival at 24 months1339
c l i n i ca l i nves t iga t i on F Maduell et al.: Adequate Kt dose(October 2013 to September 2015) compared to those who do not
get it, as well as to assess whether patients receiving a greater dose
obtain more beneﬁt. Therefore, the primary outcome variable was
the time to occurrence of death from any cause and its association
with the dialysis dose group. A key secondary outcome was to
measure the same association with hospitalization risk.
Study population
The inclusion criteria for our study population were adult patients
(aged >18 years), receiving thrice weekly standard HD for
>6 months at any Spanish FMC center. The patients must have had
5 or more valid measures of Kt during each month. The exclusion
criteria were liver cirrhosis or neoplasms. All of these criteria were
applied to patients monthly (see Supplementary Table S1 for further
details). Given that this was not an interventional study, nephrolo-
gists followed current clinical recommendations, and dialysis dose
was prescribed according to Spanish FMC guidelines (Kt/V $ 1.4).
Kt measured by ionic dialysance was divided by V, as measured by
bioelectrical impedance with the BCM device or calculated using
Watson’s formula.
Treatment procedures and study variables
The patients were dialyzed with 4008S or 5008 (Fresenius Medical
Care) monitors, equipped with OCM sensors. These devices allow
automatic noninvasive measurement of the dialysis dose during each
dialysis treatment. This system measures the effective in vivo urea
clearance (K) and calculates the accumulated Kt.35 The Fresenius
machine time setting to adjust the frequency of Kt measurements
was 30 minutes in all dialysis units.
The target Kt was calculated monthly for each patient using the
following algebraic expression: minimum target Kt in liters ¼ 1/
[0.0069 þ (0.0237/BSA)], with BSA in m2 ¼ weight0.425 
height0.725  0.007184, with weight (post-dialysis dry body weight)
expressed as kilograms and height measured in centimeters.9–10
Thus, the adequate dialysis dose was calculated by the difference
between achieved Kt and target Kt (achieved Kt – target Kt), referred
to as achieved–targetKt. As an example, Supplementary Table S4 con-
tains several Kt targets individualized for BSA and used in this study.
Based on achieved–targetKt deciles obtained in a previous study,
12
the HD population was assigned monthly to 1 of 10 groups: lower
than –8 L, –8 to –4 L, –4 to –1 L, –1 to þ1 L (the reference
group), þ1 to þ3 L, þ3 to þ6 L, þ6 to þ9 L, þ9 to þ12 L, þ12
to þ15 L, or higher than þ15 L.
The following parameters were recorded and grouped as non-
modiﬁable factors: age, gender, cardiovascular risk factors (catego-
rized as yes/no),36 diabetes mellitus status (categorized as yes/no),
Charlson index; or grouped as modiﬁable factors: treatment
technique, HD or post-dilution online HDF dialysis mode, hospi-
talization/death dates, achieved Kt, target Kt, dialyzer, Td, QB, post-
dialysis body weight, height, and vascular access in use (categorized
as AVF or catheter; prosthetic arteriovenous ﬁstula was included in
the AVF category). Additionally, the following laboratory data were
recorded: albumin, C-reactive protein, and hemoglobin. Residual
renal function was not recorded because of missing data.
Statistical analyses
The variables were grouped according to 10 categories of the achieved–
targetKt. Qualitative variables are shown as percentages and quanti-
tative variables as means accompanied by their corresponding
standard deviations or medians and their corresponding 25th and
75th percentiles as appropriate. The chi-square test was used to1340compare qualitative variables, the Wilcoxon rank-sum test for
continuous parameters not normally distributed and ANOVA
for continuous normally distributed variables, with logarithmic
transformations applied to CRP because of heavy positive skewness.
Further post hoc multiple range tests (Scheffé) were performed to
compare the signiﬁcant groups in the corresponding ANOVA test.
To identify factors predicting the achievement of the minimum
target Kt session by session in the study, generalized linear mixed
models analyses were performed, using the GENLINMIXED SPSS
module.37 These mixed-effects logistic regression models were built
considering the patients as repeated measures. Moreover, in an effort
to incorporate consideration of the different prescribing strategies of
treatment modalities in the different centers, Spanish FMC facilities
were included in the model as a random effect.
The linear effect of the continuous variables was explored in
several univariate models. Only those variables with risk showing a
linear effect over the outcome were introduced as continuous vari-
ables. The corresponding cutoffs were chosen in a clinically mean-
ingful way in an effort to yield balanced groups. For HD vintage,
these cutoffs were <2.00, 2.00 to 2.99, 3.00 to 4.99, 5.00 to 8.00, and
>8.00 years. For age, these were <51, 51 to 60, 61 to 70, 71 to 80,
and >80 years. For weight, these were <58, 58 to 64, 65 to 72, 73 to
81, and >81 kg. For albumin, these were <3.50, 3.51 to 4.00, and
>4.00 g/dl. For hemoglobin, these were <10.00, 10.01 to 11.00,
11.01 to 12.00, 12.01 to 13.00, and >13.00 g/dl. For C-reactive
protein, these were <1.20, 1.21 to 3.40, 3.41 to 7.00, 7.01 to 15.00,
and >15.00 mg/l.
The primary and secondary outcomes of this trial were to eval-
uate if the dialysis dose measured by Kt and properly adjusted for
BSA improved the morbidity–mortality status of the patients. To
examine this possibility, univariate Cox proportional hazard
regression models were performed to estimate the corresponding
HRs for all of the achieved–targetKt groups using a time-dependent
variable for the Kt category. Moreover, the corresponding multi-
variate Cox models were built including all the nonmodiﬁable and
modiﬁable factors recorded. The nonlinear nature of the relationship
between the different covariates and the outcome was considered, as
described above. To control for the possible unit effect on mortality,
a covariate analysis with the different centers involved in the study
was performed. The group containing the null value for the achieved–
targetKt parameter was selected as reference for these analyses. Trend
test and conﬁdence intervals at 95% were calculated for every
regression model.
As a sensibility analysis, we used a propensity score matching
procedure to deal with the potential reverse causality issue. Then we
calculated the propensity score for each patient by modeling the
probability of receiving an HD dose equal to or less than (achieved–
targetKt 1 to þ1 L) or more (> þ1 to þ3 L) than the reference
group at baseline. The corresponding logistic regression models were
built, introducing into the model all of the predictors with an impact
on the nonachievement of the target Kt previously deﬁned (Table 2)
and Kt/V. We subsequently used the derived propensity scores to
match in a 1:1 ratio both groups using a caliper matching algorithm.
We used this type of matching procedure, ﬁxing a caliper parameter
equivalent to 0.2 of the pooled standard deviation of the logit of the
propensity scores.38 To evaluate the quality of the propensity score
matching, we assessed the balance in covariates by the absolute
difference before and after matching between the groups and the
proper statistical comparisons.
The statistical analyses in this work were performed using
SPSS 23.0 (IBM Armonk, NY). The propensity score matching wasKidney International (2016) 90, 1332–1341
F Maduell et al.: Adequate Kt dose c l i n i ca l i nves t iga t ionimplemented with an SPSS R-menu for propensity score matching39
using R statistical free software version R3.1.1. A P value < 0.05 was
considered statistically signiﬁcant.
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